Related Experiment Video

Updated: Jul 24, 2025

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

9.0K

Monoclonal Antibodies in Oncology: A Decade of Novel Options

Vaibhavi Kardile1, Atharva Kulkarni1, Brinda Nadar1

  • 1Department of Pharmacology, AISSMS College of Pharmacy, Pune, India.

Cell Biochemistry and Biophysics
|July 3, 2023
PubMed

Insights

Monoclonal antibodies (mAbs) are effective cancer treatments, with many new approvals in the last decade. This review systematically compiles recently approved oncology mAbs and their mechanisms of action for professionals.

Area of Science:

  • Oncology
  • Immunotherapy
  • Drug Development

Background:

  • Monoclonal antibodies (mAbs) have demonstrated significant efficacy in treating various cancers, including solid tumors and hematological malignancies.
  • Several top-selling drugs are mAbs, with pembrolizumab projected to be the highest revenue-generating drug by 2024.
  • A substantial number of oncology mAbs have received regulatory approval in the past decade, necessitating updated information for healthcare professionals.

Purpose of the Study:

  • To provide a systematic compilation of monoclonal antibodies (mAbs) approved by the US FDA for cancer treatment within the last decade.
  • To elaborate on the mechanisms of action for newly approved oncology mAbs.
  • To offer a comprehensive update on the landscape of monoclonal antibodies in cancer therapy.

Main Methods:

  • Systematic review of monoclonal antibodies (mAbs) approved by the US FDA.
  • Literature search using "Drugs at FDA" and PubMed databases.
  • Data collection and analysis of approved mAbs from 2010 to the present.

Main Results:

  • Identification and compilation of numerous monoclonal antibodies (mAbs) approved for oncological indications in the past decade.
  • Detailed explanation of the mechanisms of action for recently approved mAbs.
  • Overview of the evolving role and increasing number of mAbs in cancer treatment.

Conclusions:

  • Monoclonal antibodies (mAbs) represent a rapidly expanding and crucial class of drugs in modern oncology.
  • This review serves as an essential resource for clinicians and researchers to stay updated on the latest advancements in mAb therapy.
  • Understanding the mechanisms of action of these novel agents is key to optimizing their clinical application in cancer treatment.
Keywords:
CancerConjugated mAbsImmune checkpointsMechanism of actionMonoclonal antibodies

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.4K
Generation of Murine Monoclonal Antibodies by Hybridoma Technology09:42

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

41.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
15.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
573
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K